首页> 外文期刊>Virology Journal >Co-receptor usage and prediction of v3 genotyping algorithms in hiv-1 subtype b' from paid blood donors experienced anti-retroviral therapy in chinese central province
【24h】

Co-receptor usage and prediction of v3 genotyping algorithms in hiv-1 subtype b' from paid blood donors experienced anti-retroviral therapy in chinese central province

机译:在中部省份,有偿献血者在hiv-1 b'亚型b'中共同受体的使用和v3基因分型算法的预测经历了抗逆转录病毒治疗

获取原文
           

摘要

Background This study explored co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province in order to design effectively therapeutic regimen. Methods HIV-1 strains were isolated in treatment HIV-1 infections and treatment-na?ve HIV-1 infections, then co-receptor usage of HIV-1 strains was identified based on Ghost cell lines using flow cytometry. HIV-1 V3 region was amplified and submitted into web-server (WebPSSM and geno2pheno) to predict HIV-1 co-receptor usage. The feasibility of prediction HIV-1 usage with Web-server assay was analyzed by comparing prediction of V3 genotyping algorithms with HIV phenotype assay based on Ghost cell line. Results 45 HIV-1 strains and 114 HIV-1 strains were isolated from HIV-1 infections exposed anti-retroviral therapy and treatment-na?ve, respectively. 41% clinical viruses from ART patients and 18% from treatment-na?ve patients used CXCR4 as co-receptor. The net charge in the V3 loop was significantly difference in both groups. The sensitivity and specificity for predicting co-receptor capacity is 54.6% and 90.0% on 11/25 rule, 50.0% and 90% on Web-PSSMx4r5, 68.2% and 40.0% on Geno2pheno[co-receptor]. Conclusion Dual/mixed/X4 co-receptor utilization was higher in ART patients than treatment-na?ve patients. It is should paid attention to predicting HIV-1 co-receptor usage based on V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.
机译:背景:本研究探讨了中部省份有偿抗逆病毒治疗的付费献血者中HIV-1 B'亚型B'中V3基因分型算法的共受体用法和预测,以设计有效的治疗方案。方法分离HIV-1菌株用于治疗HIV-1感染和初治HIV-1感染,然后利用流式细胞术根据Ghost细胞系鉴定HIV-1菌株的共同受体使用。 HIV-1 V3区域被扩增并提交到Web服务器(WebPSSM和geno2pheno)中,以预测HIV-1共受体的使用。通过比较V3基因分型算法的预测与基于Ghost细胞系的HIV表型分析的预测,分析了通过Web服务器分析预测HIV-1使用的可行性。结果从分别接受抗逆转录病毒治疗和初次治疗的HIV-1感染中分离出45株HIV-1毒株和114株HIV-1毒株。来自ART患者的41%临床病毒和从未接受过治疗的患者中有18%使用CXCR4作为共受体。 V3回路中的净电荷在两组中均显着不同。预测共受体能力的敏感性和特异性在11/25法则上分别为54.6%和90.0%,在Web-PSSM x4r5 上分别为50.0%和90%,在Geno2pheno 上分别为68.2%和40.0% [共同受体] 。结论ART患者中双重/混合/ X4联合受体利用率高于未接受过治疗的患者。在中部省经历过抗逆转录病毒治疗的有偿献血者中,应注意根据HIV-1 B型亚型的V3基因分型算法预测HIV-1共同受体的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号